Psychotomimetic agent BZ (3-quinuclidiny benzilate)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F15%3A50004534" target="_blank" >RIV/62690094:18470/15:50004534 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/15:10320672

Výsledek na webu

<a href="http://dx.doi.org/10.1016/B978-0-12-800159-2.00012-9" target="_blank" >http://dx.doi.org/10.1016/B978-0-12-800159-2.00012-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/B978-0-12-800159-2.00012-9" target="_blank" >10.1016/B978-0-12-800159-2.00012-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Psychotomimetic agent BZ (3-quinuclidiny benzilate)

Popis výsledku v původním jazyce

Agent BZ is the code name for 3-quinuclidinyl benzilate, an anticholinergic ester of glycolic acid. BZ is a PCW agent described as an anticholinergic hallucinogen. BZ is a competitive inhibitor of the effects of ACh acting at the postsynaptic muscarinic receptors in the PNS and CNS. In the PNS, this inhibition is observed in the muscle, autonomic ganglia, and exocrine glands. BZ's ability to readily cross the blood-brain barrier causes mental status changes and delirium. BZ is one of the most potent anticholinergic psychotomimetics known with only small doses necessary to produce incapacitation. BZ at single doses of less than 1 mg produces delirium lasting several days. BZ is usually disseminated as an aerosol, and the primary route of absorption is through the respiratory system. Absorption also can occur through the skin or by gastrointestinal tract absorption. The pharmacologic activity of BZ is similar to atropine or scopolamine but with a much longer duration of action. Physicochemical properties and biological effects of BZ are described. The effect is characterized by vegetative symptoms progressing to hallucinations. Distribution of BZ in the body is preferably in the peripheral, followed by the CNS. Its mechanism of effect is based on its interaction with cholinergic receptors in the CNS and PNS, and the resulting lack of a neuromediator-ACh. The antidotal effect against BZ intoxication is based on an increase of ACh levels caused by reversible cholinesterase inhibitors. From this group of compounds, physostigmine was used as the first antidote against BZ. However, physostigmine has a very thin margin between its therapeutic and toxic doses. Therefore, new inhibitors were developed, and acridine derivatives were found to be the most promising. From these compounds, 7-MEOTA was the most effective. It is less toxic than physostigmine and tacrine and its central effect is pronounced. It was introduced in the Czech army as an antidote against BZ poisoning.

Název v anglickém jazyce

Psychotomimetic agent BZ (3-quinuclidiny benzilate)

Popis výsledku anglicky

Agent BZ is the code name for 3-quinuclidinyl benzilate, an anticholinergic ester of glycolic acid. BZ is a PCW agent described as an anticholinergic hallucinogen. BZ is a competitive inhibitor of the effects of ACh acting at the postsynaptic muscarinic receptors in the PNS and CNS. In the PNS, this inhibition is observed in the muscle, autonomic ganglia, and exocrine glands. BZ's ability to readily cross the blood-brain barrier causes mental status changes and delirium. BZ is one of the most potent anticholinergic psychotomimetics known with only small doses necessary to produce incapacitation. BZ at single doses of less than 1 mg produces delirium lasting several days. BZ is usually disseminated as an aerosol, and the primary route of absorption is through the respiratory system. Absorption also can occur through the skin or by gastrointestinal tract absorption. The pharmacologic activity of BZ is similar to atropine or scopolamine but with a much longer duration of action. Physicochemical properties and biological effects of BZ are described. The effect is characterized by vegetative symptoms progressing to hallucinations. Distribution of BZ in the body is preferably in the peripheral, followed by the CNS. Its mechanism of effect is based on its interaction with cholinergic receptors in the CNS and PNS, and the resulting lack of a neuromediator-ACh. The antidotal effect against BZ intoxication is based on an increase of ACh levels caused by reversible cholinesterase inhibitors. From this group of compounds, physostigmine was used as the first antidote against BZ. However, physostigmine has a very thin margin between its therapeutic and toxic doses. Therefore, new inhibitors were developed, and acridine derivatives were found to be the most promising. From these compounds, 7-MEOTA was the most effective. It is less toxic than physostigmine and tacrine and its central effect is pronounced. It was introduced in the Czech army as an antidote against BZ poisoning.

Druh

C - Kapitola v odborné knize

CEP obor

KA - Vojenství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Handbook of toxicology of chemical warfare agents

ISBN

978-0-12-800159-2

Počet stran výsledku

8

Strana od-do

151-158

Počet stran knihy

1184

Název nakladatele

Elsevier

Místo vydání

Amsterdam

Kód UT WoS kapitoly

—